In May 2026, the international medical community reached a significant milestone: Polycystic Ovary Syndrome (PCOS) was officially renamed Polyendocrine Metabolic Ovarian Syndrome (PMOS). More than a change in terminology, the new name reflects a fundamental shift in how the condition is understood – from a disorder viewed primarily through a reproductive lens to a complex endocrine…
Details
Since February 2023, two UK clinics gradually rolled out three modules — hypertension (HTN), type 2 diabetes (DM2), hypercholesterolemia (HCL) — with a clinical usage that was systematically monitored (by Metadvice) for diagnosis and therapies so that the recommendations can now be linked with observable outcomes (stored by Electronic Medical Record systems, EMR independent from…
DetailsEASD conference, 15 – 19 September 2025 in Vienna. Can we De-Escalate Pharmaco-Therapies For Certain Patients Living with Type 2 Diabetes and Chronic Kidney Disease? Zeina Gabr, Louis-Alexandre Leger, Samia Kidwai, Andrew Krentz, André Jaun Download PDF
Details